Investigators developed C391, a potent proteinase-activated receptor-2 (PAR2) antagonist effective in blocking peptidomimetic- and trypsin-induced PAR2 signaling in vitro as well as reducing inflammatory PAR2-associated pain in vivo.
[British Journal of Pharmacology]